ASP Isotopes (NASDAQ:ASPI) Stock: Insider Robert John Andrew Ryan Acquires 8,000 Shares

ASP Isotopes Inc. (NASDAQ:ASPI) Director John Ryan acquired 8,000 shares of the company’s stock in a transaction dated Monday, September 28th. The shares were bought at an average price of $2.70 per share, for a total transaction of $21,600.00. Following the purchase, the director owned 660,222 shares in the company, valued at approximately $1,782,599.40. This represents a 1.23% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

ASP Isotopes Trading Up 1.2%

ASPI stock opened at $2.63 on Wednesday. The company has a fifty day moving average price of $3.77 and a two-hundred day moving average price of $4.93. The company has a debt-to-equity ratio of 0.76, a current ratio of 3.87 and a quick ratio of 3.85. The stock has a market cap of $403.21 million, a price-to-earnings ratio of -1.99 and a beta of 3.59. ASP Isotopes Inc. has a one year low of $2.51 and a one year high of $14.49.

ASP Isotopes (NASDAQ:ASPI) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.11). ASP Isotopes had a negative net margin of 427.98% and a negative return on equity of 64.99%. The business had revenue of $5.12 million during the quarter, compared to analyst estimates of $4.47 million.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on ASPI shares. Weiss Ratings restated a “sell (d-)” rating on shares of ASP Isotopes in a research report on Monday, September 21st. Wall Street Zen upgraded ASP Isotopes from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 22nd. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $13.00.

Institutional Trading of ASP Isotopes

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ASPI. BlackRock Inc. bought a new stake in ASP Isotopes during the second quarter worth about $57,331,000. Encompass Capital Advisors LLC purchased a new stake in shares of ASP Isotopes during the first quarter valued at approximately $30,551,000. Alyeska Investment Group L.P. increased its position in shares of ASP Isotopes by 5.6% during the second quarter. Alyeska Investment Group L.P. now owns 2,843,503 shares of the company’s stock valued at $17,687,000 after acquiring an additional 151,337 shares in the last quarter. AWM Investment Company Inc. bought a new stake in shares of ASP Isotopes during the second quarter valued at approximately $9,837,000. Finally, Philadelphia Financial Management of San Francisco LLC purchased a new position in ASP Isotopes in the 2nd quarter worth approximately $8,353,504. Hedge funds and other institutional investors own 16.80% of the company’s stock.

ASP Isotopes Company Profile

ASP Isotopes Inc (NASDAQ: ASPI) is a development-stage company focused on isotope enrichment and related technologies. The company is developing an isotope-separation platform known as the Aerodynamic Separation Process, which is intended to enrich selected chemical elements and isotopes for use in several specialized markets.

ASP Isotopes has identified applications in the nuclear energy, medical, semiconductor, and quantum-computing industries. Its development programs have included uranium enrichment as well as the production of specialty isotopes such as carbon-14, molybdenum-100, and silicon-28.